Skip to content

Study · In vitro (cells) · rat and mouse · 1996

4 results

Thymosin alpha 1 interacts with the VIP receptor-effector system in rat and mouse immunocompetent cells.

Pozo D, Guerrero JM, Segura JJ, Calvo JR

Immunopharmacology1 Sept 1996Cited by 2 (Europe PMC)

PMID8886855 (opens in a new tab)DOI10.1016/0162-3109(96)00131-2 (opens in a new tab)PepBankPUB-08886855
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In rat and mouse immune cells, thymosin alpha‑1 inhibited 125I-VIP binding with a potency 1000-1700 times lower than that of native VIP.

    In plain wordsIn rat and mouse immune cells in lab tests, thymosin alpha‑1 blocked VIP binding, but far more weakly than VIP itself.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseInhibition of 125I-VIP binding
    Study

    rat and mousen: not reported in source

    peritoneal macrophages, peripheral blood lymphocytes and spleen lymphocytes
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    10(-11) to 10(-6) MAs given in this study (rat and mouse).

    Measurements

    Potency relative to native VIP
    1000 to 1700 times lower
    125I-VIP binding, all models

    Source sentences

    Summary
    In all models, thymosin alpha 1 inhibits 125I-VIP binding with a potency that is in a range 1000-1700 times lower than that of the native VIP.
    1 context sentence
    Summary · context
    Thymic peptide thymosin alpha 1 (10(-11) to 10(-6) M) is shown to interact with the VIP receptor-effector system in rat and mouse peritoneal macrophages, and both rat peripheral blood lymphocytes and spleen lymphocytes.
  2. 02LabIn vitro (cells)Activity measurement

    In rat and mouse immune cells, thymosin alpha‑1 was the weakest of the VIP, helodermin, PHI, secretin and thymosin alpha‑1 series in inhibiting 125I-VIP binding.

    In plain wordsIn lab tests on rat and mouse cells, thymosin alpha‑1 blocked VIP binding less than VIP, helodermin, PHI or secretin.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableOrder of potency against VIP-related peptides
    Study

    rat and mousen: not reported in source

    peritoneal macrophages, peripheral blood lymphocytes and spleen lymphocytes
    Comparator
    VIP, helodermin, PHI, secretin
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The order of potency in inhibiting 125I-VIP binding was VIP > helodermin > PHI > secretin > thymosin alpha 1.
    1 context sentence
    Summary · context
    Thymic peptide thymosin alpha 1 (10(-11) to 10(-6) M) is shown to interact with the VIP receptor-effector system in rat and mouse peritoneal macrophages, and both rat peripheral blood lymphocytes and spleen lymphocytes.
  3. 03LabIn vitro (cells)Activity measurement

    In rat and mouse immune cells, thymosin alpha‑1 was weak in stimulating adenylyl cyclase activity, with an efficacy 900-1800 times lower than that of native VIP.

    In plain wordsIn rat and mouse cells in lab tests, thymosin alpha‑1 only weakly switched on adenylyl cyclase, far less than VIP.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseAdenylyl cyclase stimulation
    Study

    rat and mousen: not reported in source

    peritoneal macrophages, peripheral blood lymphocytes and spleen lymphocytes
    Comparator
    Native VIP
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    10(-10) to 10(-6) MAs given in this study (rat and mouse).

    Measurements

    Efficacy relative to native VIP
    900 to 1800 times lower
    adenylyl cyclase stimulation, all cell types

    Source sentences

    Summary
    Thymosin alpha 1 (10(-10) to 10(-6) M) was weak in stimulating adenylyl cyclase activity. Its efficacy is in a range 900-1800 times lower than that of native VIP in all cell types studied.
    1 context sentence
    Summary · context
    Thymic peptide thymosin alpha 1 (10(-11) to 10(-6) M) is shown to interact with the VIP receptor-effector system in rat and mouse peritoneal macrophages, and both rat peripheral blood lymphocytes and spleen lymphocytes.
  4. 04LabIn vitro (cells)Mechanism

    The authors conclude that thymosin alpha‑1 is a VIP receptor antagonist with weak intrinsic activity and the lowest partial agonist of the VIP family.

    In plain wordsIn lab tests on rat and mouse cells, thymosin alpha‑1 acted as a weak partial activator and blocker of the VIP receptor.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableClassification at the VIP receptor
    Study

    rat and mousen: not reported in source

    peritoneal macrophages, peripheral blood lymphocytes and spleen lymphocytes
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Taken together, experimental data support that thymosin alpha 1 must be included like the lowest partial agonist of the VIP family of polypeptides and it is a VIP receptor antagonist with weak intrinsic activity.
    1 context sentence
    Summary · context
    Thymic peptide thymosin alpha 1 (10(-11) to 10(-6) M) is shown to interact with the VIP receptor-effector system in rat and mouse peritoneal macrophages, and both rat peripheral blood lymphocytes and spleen lymphocytes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.